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Methods: A single center retrospective chart review was performed on all CLI patients
who underwent endovascular treatment for IP disease from 2006 to 2010. Patient and
procedural variables were compared amongst IP CTOs and non-CTOs.
Results: Baseline characteristics and procedural variables are depicted in table 1. Of 245
IP arteries intervened upon, 40% were CTOs. Mean CTO length was 100 mm and 21%
had moderate to severe calcification. Successful recanalization was achieved in 82% of
CTOs using standard guide wire and catheter technique. When compared to non-CTOs,
CTOs were longer, had a lower number of concomitant patent run-off vessel(s) and more
likely to undergo laser atherectomy and stent deployment. Predictor of failure to cross a
CTO included moderate-severe calcification (44% vs. 15%, p  0.009) but not lesion
length (103 vs. 108 mm, p 0.8.) 6 month target vessel revascularization (31% vs. 22%,
p  0.4) and restenosis (48% vs 38%, p  0.3) rates were not significantly different
between the CTO and non-CTO groups. One year major amputation rates (21% vs. 17%,
p0.4) were also similar between the two groups.
Variable CTO (n98)
non-CTO
(n147) P value
Baseline Patient Characteristics
Age, years 66 (59-77) 63 (58-77) 0.5
Male (%) 51 (52) 89 (60) 0.2
Diabetes (%) 70 (71) 97 (68) 0.6
Prior smoker (%) 50 (51) 92 (63) 0.08
GFR, mg/dl 49 (17-68) 53 (32-85) 0.06
CAD (%) 42 (43) 79 (54) 0.1
HbA1C, % 7.5 (6.2-9.0) 7.7 (6.9-9.4) 0.04
Rutherford class 0.4
1-3 5 (5) 12 (9)
4-6 93 (95) 135 (91)
Ankle brachial index 0.56 (0.39-0.88) 0.61 (0.46-0.76) 0.7
Toe brachial index 0.28 (0.17-0.31) 0.31 (0.23-0.39) 0.02
Angiographic Characteristics
Length, mm 100 (40-130) 40 (20-120) 0.001
Calcification
None-mild 76 (79) 127 (86) 0.14
Moderate-severe 20 (21) 20 (14)
Runoff 0.001
0-1 68 (82) 63 (53)
2-3 15 (18) 57 (48)
Treatment Characteristics
Cutting balloon 5 (5) 23 (16) 0.01
Cryotherapy 7 (7) 10 (7) 0.9
Atherectomy 0.001
Laser 24 7
Excisional 1 2
Rotational 0 1
Stent placed (%) 8 (8) 2 (1) 0.008
Lesion Outcomes
Dissection 5 (5) 2 (1) 0.09
Perforation 3 (3) 0 (0) 0.06
Procedural Success 80 (82) 143 (98) 0.001
Conclusions: High procedural success and low complication rates can be achieved
during recanalization of IP CTOs by standard guide wire and catheter techniques. These
results will provide a baseline for evaluation of the results of new CTO crossing devices
and retrograde CTO recanalization.
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Background: There is considerable interest for the delivery of anti-proliferative drugs for the
prevention of restenosis following intervention in patients with peripheral Artery disease. The
TAPAS system (Thermopeutix, San Diego, CA) provides targeted fluid drug delivery between
two occlusion balloons with an adjustable treatment zone. Following application, the drug may
be aspirated to prevent systemic delivery. The purpose of this study was to evaluate the
delivery of paclitaxel (PTX) to the vessel wall within the peripheral vasculature.
Methods: Twelve pigs (n 48 arteries) underwent treatment with fluid paclitaxel
(Hospira, Lake Forest, IL) utilizing the TAPAS device for targeted drug delivery to the
iliofemoral arteries. Three different concentrations of liquid PTX were tested: 0.67 mg/ml,
1.2 mg/ml and 2.0 mg/ml. PTX was diluted with saline and 50% contrast (Ultravist 300)
to final concentration. The TAPAS catheter was positioned within the iliofemoral segment
and drug was delivered in-between the system’s dual occlusion balloons (n4 target
segments per animal). The drug was allowed to dwell for either 2 or 5 mins before
aspiration. Animals were sacrificed at 3 and 24 hrs post treatment and the segments were
dissected for analysis of PTX within the vessel wall. Plasma levels of PTX levels were
also measured. Two additional pigs were treated with 2.0 mg/ml of PTX at a dwell time
of 5 mins for histopathological assessment at 24 hrs post-treatment.
Results: PTX was detected in the vessel wall in all groups with no statistical differences
between groups. The average PTX concentration in the vessel wall was 1.73 0.85g/g and
1.29  0.47 g/g at 3 and 24 hrs post treatment, respectively. The average plasma PTX
concentration was 2.36 0.50 ng/ml and 0.55 0.61 ng/ml at 3 and 24 hrs post treatment,
respectively. Histology showed no inflammation, injury or other adverse effect vs. saline/
contrast control. On average, 77% of the total drug was aspirated from the treatment site.
Conclusions: The TAPAS catheter can be used to successfully deliver paclitaxel to a target
vessel segment with minimal systemic runoff and may be an alternative to drug eluting balloon.
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Background: Little is known about the relative contribution of injury severity, total
amount of drug delivered and multiple consecutive treatments to the arterial effects of
paclitaxel coated balloon (PCB).
Methods: 41 iliofemoral arteries (of 15 swine) were treated with 1, 2 or 6 consecutive
PCB (Medrad, Indianola, PA) or uncoated balloon (Control). Histologic features after 7
days were analyzed in a multivariable logistic regression model [reference vessel
diameter, no. of balloons deployed (
cumulative drug dose), balloon-to-artery ratio
(B:ARinjury severity), PCB treatment].
Results: Injury severity quantified by the B:AR was found as the only independent predictor
[OR (95% CI)][4521 (27.8-740689)]of medial rupture/aneurysm. B:AR [OR (95% CI)][
[7.3 (3.6-14.7)] and PCB treatment [OR (95% CI)][ 1367 (6-19536)] were independent
predictors of medial smooth muscle cell loss. Unresorbed fibrin was found only in the PCB
treatment, and proportionate to the number of consecutive PCB treatments (
cumulative drug
dose) but not to injury severity (at B:AR1.25: PCBx2: 0.390.55 vs. PCBx6: 1.680.91,
p0.001); but at B:AR1.25 it was not further aggravated (PCBx6: 2.080.42)]. This was
confirmed by a significant correlation between fibrin deposition and the number of inflations
(r0.77, p0.001) but not with injury severity (r-0.11, p0.1). Interestingly, medial-intimal
inflammation was observed with multiple treatments regardless of PCB or control, while
adventitial inflammation was noted with excess injury, also regardless of treatment type
(B:AR1.25, Table).
Conclusions: Adverse effects of PCB such as aneurysmatic dilatation are most evident when
arterial injury is excessive. Multiple PCBs deployed in the same segment (and as such the
incremental cumulative drug dose) are well tolerated if the arterial injury is contained.
Histopathology
Scores
Low Balloon to Artery ratio (<1.25)
High Balloon to Artery Ratio
(>1.25)
Controlx2
(n3)
PCBx2
(n7)
Controlx6
(n9)
PCBx6
(n9)
Controlx1
(n3)
PCBx1
(n4)
PCBx6
(n6)
Fibrin/ Platelets 0  0 0.39 
0.55
0  0 1.68 
0.91†
0  0 0.20 
0.47†
2.08 
0.43
Adventitial
Inflammation
0  0 0  0 0  0 0  0 0.76 
0.92
0.34 
0.48†
0.22 
0.42*
Intima/Media
Inflammation
0  0 0.21 
0.47†
0.20 
0.71
0.84 
0.65†
0  0 0  0 0.32 
0.58*
Medial SMC Loss
(Depth)
0.05 
0.23
1 
1.58
0.51 
1.27
2.14 
1.64†
1.76 
1.26
2.37 
0.84
3.14 
1.36*
Medial SMC Loss
(Circumference)
0.05 
.23
0.34 
0.53
024 
.0.62
1.22 
0.98 †
1.15 
1.35
2.29 
0.86
1.57 
1.28
Medial Rupture/
Aneurysm
0  0 0  0 0  0 0  0 0.76 
1.13
0.57 
1.04
0.54 
0.93*
Incidence Medial
Rupture/Aneurysm
0% 0% 0% 0% 66.67% 50.00% 33.33%
*p0.05 PCBx6 (low B:AR) versus PCBx6 (high B:AR)
†p0.05 PCB versus corresponding Control
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